• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Edaravone for amyotrophic lateral sclerosis: barriers to access and lifeboat ethics.依达拉奉治疗肌萎缩侧索硬化症：获取药物的障碍与救生艇伦理
CMAJ. 2020 Mar 23;192(12):E319-E320. doi: 10.1503/cmaj.191236.
2
Edaravone for the treatment of amyotrophic lateral sclerosis.依达拉奉治疗肌萎缩侧索硬化。
Expert Rev Neurother. 2019 Mar;19(3):185-193. doi: 10.1080/14737175.2019.1581610. Epub 2019 Feb 27.
3
Edaravone in the treatment of amyotrophic lateral sclerosis: efficacy and access to therapy - a roundtable discussion.依达拉奉治疗肌萎缩侧索硬化症的疗效和治疗途径：圆桌讨论。
Am J Manag Care. 2018 Apr;24(9 Suppl):S175-S186.
4
Assessment of Use and Safety of Edaravone for Amyotrophic Lateral Sclerosis in the Veterans Affairs Health Care System.评估在退伍军人医疗保健系统中使用依达拉奉治疗肌萎缩侧索硬化症的使用情况和安全性。
JAMA Netw Open. 2020 Oct 1;3(10):e2014645. doi: 10.1001/jamanetworkopen.2020.14645.
5
Evaluation of clinical outcome and safety profile of edaravone in treatment of amyotrophic lateral sclerosis: a 72-week single-center experience.评价依达拉奉治疗肌萎缩侧索硬化症的临床疗效和安全性：一项 72 周单中心经验。
Acta Neurol Belg. 2021 Dec;121(6):1591-1597. doi: 10.1007/s13760-020-01430-2. Epub 2020 Jul 10.
6
Edaravone: a new hope for deadly amyotrophic lateral sclerosis.依达拉奉：治疗致命性肌萎缩侧索硬化症的新希望。
Drugs Today (Barc). 2018 Jun;54(6):349-360. doi: 10.1358/dot.2018.54.6.2828189.
7
Effect of edaravone therapy in Korean amyotrophic lateral sclerosis (ALS) patients.依达拉奉治疗韩国肌萎缩侧索硬化症（ALS）患者的效果。
Neurol Sci. 2020 Jan;41(1):119-123. doi: 10.1007/s10072-019-04055-3. Epub 2019 Aug 30.
8
Efficacy and safety of edaravone in treatment of amyotrophic lateral sclerosis-a systematic review and meta-analysis.依达拉奉治疗肌萎缩侧索硬化症的疗效和安全性：系统评价和荟萃分析。
Neurol Sci. 2019 Feb;40(2):235-241. doi: 10.1007/s10072-018-3653-2. Epub 2018 Nov 27.
9
Riluzole and edaravone: A tale of two amyotrophic lateral sclerosis drugs.力如太与依达拉奉：两种肌萎缩侧索硬化症药物的故事。
Med Res Rev. 2019 Mar;39(2):733-748. doi: 10.1002/med.21528. Epub 2018 Aug 12.
10
Discussing edaravone with the ALS patient: an ethical framework from a U.S. perspective.与肌萎缩侧索硬化症患者讨论依达拉奉：从美国视角看伦理框架
Amyotroph Lateral Scler Frontotemporal Degener. 2018 May;19(3-4):167-172. doi: 10.1080/21678421.2018.1425455. Epub 2018 Jan 15.

引用本文的文献

1
Genetic testing for monogenic forms of motor neuron disease/amyotrophic lateral sclerosis in unaffected family members.对未患病家庭成员进行单基因形式运动神经元病/肌萎缩侧索硬化症的基因检测。
Eur J Hum Genet. 2025 Jan;33(1):7-13. doi: 10.1038/s41431-024-01718-4. Epub 2024 Nov 5.
2
The Brain-Gut-Bone Axis in Neurodegenerative Diseases: Insights, Challenges, and Future Prospects.神经退行性疾病中的脑-肠-骨轴：见解、挑战与未来展望。
Adv Sci (Weinh). 2024 Oct;11(38):e2307971. doi: 10.1002/advs.202307971. Epub 2024 Aug 9.
3
ROS: Executioner of regulating cell death in spinal cord injury.ROS：调控脊髓损伤中细胞死亡的执行者。
Front Immunol. 2024 Jan 23;15:1330678. doi: 10.3389/fimmu.2024.1330678. eCollection 2024.
4
Approaches to Gene Modulation Therapy for ALS.肌萎缩侧索硬化症的基因调控治疗方法。
Neurotherapeutics. 2022 Jul;19(4):1159-1179. doi: 10.1007/s13311-022-01285-w. Epub 2022 Sep 6.
5
The Role and Therapeutic Potential of the Integrated Stress Response in Amyotrophic Lateral Sclerosis.整合应激反应在肌萎缩侧索硬化症中的作用和治疗潜力。
Int J Mol Sci. 2022 Jul 15;23(14):7823. doi: 10.3390/ijms23147823.
6
The Multifaceted Role of GPCRs in Amyotrophic Lateral Sclerosis: A New Therapeutic Perspective?GPCRs 在肌萎缩侧索硬化症中的多效性作用：一种新的治疗视角？
Int J Mol Sci. 2022 Apr 19;23(9):4504. doi: 10.3390/ijms23094504.
7
FUS positive juvenile ALS-diagnostic and therapeutic insights from a 16-year-old female patient.FUS阳性青少年肌萎缩侧索硬化症——来自一名16岁女性患者的诊断与治疗见解
Acta Neurol Belg. 2023 Apr;123(2):637-639. doi: 10.1007/s13760-021-01825-9. Epub 2022 Mar 15.
8
Antioxidant Therapy in Oxidative Stress-Induced Neurodegenerative Diseases: Role of Nanoparticle-Based Drug Delivery Systems in Clinical Translation.氧化应激诱导的神经退行性疾病中的抗氧化治疗：基于纳米颗粒的药物递送系统在临床转化中的作用
Antioxidants (Basel). 2022 Feb 17;11(2):408. doi: 10.3390/antiox11020408.
9
Emerging technologies for management of patients with amyotrophic lateral sclerosis: from telehealth to assistive robotics and neural interfaces.新兴技术在肌萎缩侧索硬化症患者管理中的应用：从远程医疗到辅助机器人和神经接口。
J Neurol. 2022 Jun;269(6):2910-2921. doi: 10.1007/s00415-022-10971-w. Epub 2022 Jan 21.
10
Molecular dynamics and protein frustration analysis of human fused in Sarcoma protein variants in Amyotrophic Lateral Sclerosis type 6: An In Silico approach.肌萎缩侧索硬化症 6 型中人类融合肉瘤蛋白变体的分子动力学和蛋白质受挫分析：一种计算机模拟方法。
PLoS One. 2021 Sep 29;16(9):e0258061. doi: 10.1371/journal.pone.0258061. eCollection 2021.

本文引用的文献

1
Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial.依达拉奉在明确诊断的肌萎缩侧索硬化症患者中的安全性和有效性：一项随机、双盲、安慰剂对照试验。
Lancet Neurol. 2017 Jul;16(7):505-512. doi: 10.1016/S1474-4422(17)30115-1. Epub 2017 May 15.
2
Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients.依达拉奉（MCI-186）治疗肌萎缩侧索硬化症患者疗效与安全性的验证性双盲、平行组、安慰剂对照研究。
Amyotroph Lateral Scler Frontotemporal Degener. 2014 Dec;15(7-8):610-7. doi: 10.3109/21678421.2014.959024. Epub 2014 Oct 6.
3
Effect of a novel free radical scavenger, edaravone (MCI-186), on acute brain infarction. Randomized, placebo-controlled, double-blind study at multicenters.新型自由基清除剂依达拉奉（MCI-186）对急性脑梗死的影响。多中心随机、安慰剂对照、双盲研究。
Cerebrovasc Dis. 2003;15(3):222-9. doi: 10.1159/000069318.
4
A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group.利鲁唑治疗肌萎缩侧索硬化症的对照试验。肌萎缩侧索硬化症/利鲁唑研究组
N Engl J Med. 1994 Mar 3;330(9):585-91. doi: 10.1056/NEJM199403033300901.

Edaravone for amyotrophic lateral sclerosis: barriers to access and lifeboat ethics.

作者信息

Breiner Ari, Zinman Lorne, Bourque Pierre R

机构信息

Division of Neurology (Breiner, Bourque), Department of Medicine, The Ottawa Hospital and University of Ottawa; Ottawa Hospital Research Institute (Breiner, Bourque), Ottawa, Ont.; Sunnybrook Research Institute (Zinman), Hurvitz Brain Sciences Program, Sunnybrook Health Sciences Centre; Division of Neurology (Zinman), Department of Medicine, University of Toronto, Toronto, Ont.

出版信息

CMAJ. 2020 Mar 23;192(12):E319-E320. doi: 10.1503/cmaj.191236.

DOI:10.1503/cmaj.191236
PMID:32392516
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7101182/
Abstract
摘要